To Be or Not To Be: That is the Abstract Question, Naturally
1h 31m
Created on October 27, 2016
Intermediate
Overview
In a trilogy of decisions since 2010, the Supreme Court changed its interpretation of the judicial exceptions to patentability, namely laws of nature, natural phenomena, and abstract ideas. Bilski v. Kappos, 561 U.S.593, 601, 130 S. Ct. 3218, 3225, 95 USPQ2d 1001, 1005-06 (2010); Association for Molecular Pathology v. Myriad Genetics, Inc. 569 U.S. _, 133 S. Ct. 2107, 2116, 106 USPQ2d 1972, 1979 (2013); and Alice Corp. Pty. Ltd. v. CLS Bank Int'l, 573 U.S. _, 134 S. Ct. 2347, 2354, 110 USPQ2d 1976, 1980 (2014).
In this seminar, Aasheesh Shravah and Amy Goldsmith, Intellectual Property Practice Attorneys at Tarter Krinsky & Drogin LLP, discuss the effect of these decisions on the patentability of biotech, computer
Learning Objectives:
- Understand the USPTO Guidelines for biotech, computer software and business method patents
- Recognize what the USPTO has deemed is an allowable application
- Answer the question: “What is the test for patent eligibility and how has it been interpreted by the district courts and the Federal Circuit?”
- Identify the interplay between patents, copyrights and trade secrets
Gain access to this course, plus unlimited access to 1,800+ courses, with an Unlimited Subscription.
Explore Lawline Subscriptions